@article{fdi:010084557,
  title = {{I}n vitro evaluation of therapeutic antibodies against a {SARS}-{C}o{V}-2 {O}micron {B}.1.1.529 isolate},
  author = {{T}ouret, {F}. and {B}aronti, {C}{\'e}cile and {B}ouzidi, {H}. {S}. and {L}amballerie, {X}. de},
  editor = {},
  language = {{ENG}},
  abstract = {{T}he emergence and rapid spread of the {O}micron variant of {SARS}-{C}o{V}-2, which has more than 30 substitutions in the spike glycoprotein, compromises the efficacy of currently available vaccines and therapeutic antibodies. {U}sing a clinical strain of the {O}micron variant, we analyzed the neutralizing power of eight currently used monoclonal antibodies compared to the ancestral {B}.1 {B}av{P}at1 {D}614{G} strain. {W}e observed that six of these antibodies have lost their ability to neutralize the {O}micron variant. {O}f the antibodies still having neutralizing activity, {S}otrovimab/{V}ir-7831 shows the smallest reduction in activity, with a factor change of 3.1. {C}ilgavimab/{AZD}1061 alone shows a reduction in efficacy of 15.8, resulting in a significant loss of activity for the {E}vusheld cocktail (42.6-fold reduction) in which the other antibody, {T}ixagevimab, does not retain significant activity against {O}micron. {O}ur results suggest that the clinical efficacy of the initially proposed doses should be rapidly evaluated and the possible need to modify doses or propose combination therapies should be considered.},
  keywords = {},
  booktitle = {},
  journal = {{S}cientific {R}eports - {N}ature},
  volume = {12},
  numero = {1},
  pages = {4683 [5 p.]},
  ISSN = {2045-2322},
  year = {2022},
  DOI = {10.1038/s41598-022-08559-5},
  URL = {https://www.documentation.ird.fr/hor/fdi:010084557},
}